1. "Thoracic Oncology"
Formats
  1. Meeting Abstract (1694)
  2. Journal Article (1416)
  3. Review (80)
  4. Editorial (56)
  5. Book Section (35)
  6. Guidelines (24)
  7. Conference Paper (21)
  8. Correspondence (10)
  9. Research Letter (7)
  10. Miscellaneous (6)
  11. Book Whole (2)
Groups
  1. Department of Medicine (3351)
  2. Solid Tumor Oncology Division (3351)
  3. Thoracic Oncology (3351)
  4. GSK Faculty (1056)
  5. Department of Pathology and Laboratory Medicine (797)
  6. Human Oncology and Pathogenesis Program (625)

More Groups

People
  1. Mark Kris (869)
  2. Alexander Drilon (631)
  3. Gregory Riely (599)
  4. Charles Rudin (488)
  5. Marc Ladanyi (414)
  6. Matthew Hellmann (411)

More People

Years
  1. 2025 (73)
  2. 2024 (270)
  3. 2023 (272)
  4. 2022 (337)
  5. 2021 (337)
  6. 2020 (258)

More Years

Publications
  1. Journal of Clinical Oncology (692)
  2. Journal of Thoracic Oncology (513)
  3. Annals of Oncology (277)
  4. Clinical Cancer Research (156)
  5. Cancer Research (128)
  6. International Journal of Radiation Oncology, Biology, Physics (89)

More Publications

Publishers
  1. American Society of Clinical Oncology (769)
  2. Elsevier Inc. (734)
  3. American Association for Cancer Research (383)
  4. Oxford University Press (350)
  5. Nature Publishing Group (148)
  6. Elsevier Science, Inc. (78)

More Publishers

Results (3351)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of patritumab deruxtecan (HER3-DXd) in patients (pts) with advanced KRAS G12C non-small cell lung cancer (NSCLC): Study U102 cohort 5
    Meeting Abstract

    Paz-Ares, L.; Steuer, C.; Ruiter, G.; Nishio, M.; Murakami, H.; Kim, D. W.; Felip, E.; Baik, C. S.; Lin, C. C.; Massarelli, E.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • A randomized phase III study of ivonescimab versus pembrolizumab as first-line treatment of metastatic non-small cell lung cancer as first-line treatment of metastatic non-small cell lung cancer with high tumor PD-L1 expression: HARMONi-7
    Meeting Abstract

    Passaro, A.; Girard, N.; Rodriguez Abreu, D.; Gumus, M.; Wu, Y. L.; Syrigos, K.; Ramlau, R.; Santos, E.; Berz, D.; Gandhi, C.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • TROPION-Lung15: A phase III study of datopotamab deruxtecan (Dato-DXd) ± osimertinib vs platinum doublet chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) and disease progression on prior osimertinib
    Meeting Abstract

    Nadal, E.; Cheema, P. K.; Wu, Y. L.; Ahn, M. J.; Tanizaki, J.; Gharagoozloo, S.; Nizialek, E.; Shi, X.; van der Gronde, T.; Yu, H. A.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Enhancing enrollment to 1L NSCLC trials by allowing 1 prior cycle of standard of care (SOC): SUNRAY-01 experience
    Meeting Abstract

    Hochmair, M. J.; Arbour, K. C.; Negrao, M. V.; Cappuzzo, F.; Dingemans, A. M. C.; Girard, N.; Gronberg, B. H.; Leal, T. A.; Lindsay, C.; Lu, S.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with METexon 14 (METex14) skipping non-small cell lung cancer (NSCLC) from the VISION study: ≥3-year follow-up outcomes
    Meeting Abstract

    Mazieres, J.; Veillon, R.; Cortot, A.; Ferrara, R.; Felip, E.; Garassino, M.; Le, X.; Thomas, M.; Sakai, H.; Smit, E.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Efficacy outcomes of larotrectinib by prior therapy and performance status in patients with TRK fusion lung cancer
    Meeting Abstract

    Moreno Garcia, V.; Drilon, A.; Kummar, S.; Lin, J. J.; Tan, D. S. W.; Rieke, D. T.; Dubashi, B.; Kunhiparambath, H.; Burcoveanu, D. I.; Neu, N.; more...
    Journal of Thoracic Oncology (2025)

    Fulltext@MSK | Save
  • Things you should know about managing ALK plus metastatic NSCLC
    Editorial

    Kris, M. G.; Gainor, J.; Preeshagul, I.; Yu, H. A.
    Oncology (Norwalk) (2025)

    Fulltext@MSK | Save
  • Can longitudinal biomarkers guide treatment decisions? Time will tell
    Editorial

    Jeng, M. Y.; Schoenfeld, A. J.
    Clinical Cancer Research (2025)

    Fulltext@MSK | Save
  • Emerging importance of HER3 in tumorigenesis and cancer therapy
    Review

    Garrett, J. T.; Tendler, S.; Feroz, W.; Kilroy, M. K.; Yu, H.
    Nature Reviews Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Genetic ancestry-based differences in biomarker-based eligibility for precision oncology therapies
    Journal Article

    Arora, K.; Suehnholz, S. P.; Zhang, H.; Ostrovnaya, I.; Kundra, R.; Nandakumar, S.; Nissan, M. H.; Brannon, A. R.; Bandlamudi, C.; Ladanyi, M.; more...
    JAMA Oncology (2025)

    Fulltext@MSK | Save